R&D Center

PCG-BIOTECH aims to develop innovative anticancer drugs with fewer side effects.

Pipeline

Indication Pipeline Platform Development Stage
Target
Validation
Discovery
(Hit to Lead)
Lead
Optimization
PreClinical
Development
IND
enabling
PhaseⅠ PhaseⅡ PhaseⅢ
Acute Myeloid Leukemia
(AML)
PCG-C001
(First-in-Class)
Chemical            
Metastatic Triple-Negative Breast Cancer
(TNBC)
PCG-C002
(First-in-Class)
Ab/ADC              
PCG-C003
(First-in-Class)
Chemical              
Metastatic Colorectal Cancer
(CC)
PCG-C004
(First-in-Class)
Ab/ADC              
Huntington's disease
(HD)
PCG-N001
(First-in-Class)
Chemical              
Small Cell Lung Cancer
(SCLC)
PCG-C005
(First-in-Class)
Ab/
Chemical
             
Liver Cancer
(LC)
PCG-C006
(First-in-Class)
Ab/ADC              
Bipolar Disorder
(ND)
PCG-N002
(First-in-Class)
Chemical              
Degenerative Diseases
(AD, PD)
PCG-N003
(First-in-Class)
Ab/ADC